CAMPTH-1H&TACROLIMUS FOLLOWED BY IMMUNOSUPPRESS WITHDRAWAL IN LIVER TRANSPLANTS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究的目的是确定2个剂量的Campath-1H，然后是一种称为他克莫司（Tacrolimus，简称TMF）的抗排斥药物，是否可以安全有效地预防供体肝脏的排斥反应。本研究还将评价Campath-1H诱导“耐受性”的能力。耐受性是指即使您没有服用免疫抑制剂，身体也不再试图排斥移植的肝脏。在这项研究中，用于预防排斥反应的抗排斥药物（他克莫司）将逐渐停用，从肝移植后一年肝功能稳定开始。如果确定受试者可以逐渐停用他克莫司，则受试者将重新同意参加本研究的退出部分。停药部分将持续一年，包括每周一次和每两周一次的访视，以逐渐停用他克莫司。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if 2 doses of Campath-1H, followed by one anti-rejection drug called tacrolimus (Prograf), will be safe and effective in preventing rejection of the donor liver. This study will also evaluate the ability of the Campath-1H to induce "tolerance". Tolerance is when the body no longer tries to reject the transplanted liver even when you are not taking immunosuppression. During this study, the anti-rejection medication (tacrolimus) used to prevent rejection will be gradually withdrawn, beginning one year after liver transplant liver function is stable. If it is determined that the subject can gradually withdraw tacrolimus and then the subject will be re-consented to take part in the withdrawal portion of this study. The withdrawal component will last one year and involve weekly and bi-weekly visits to allow a gradual weaning of the tacrolimus.